Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine IR for Motor Fluctuations in Advanced Parkinson's Disease
NCT06817200Phase 2Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- May 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Amantadine with Placebo (2 arms). Primary endpoint: Change in motor fluctuation (Off-time) at 3 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
amantadine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06817200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06817200.